BARCELONA, Spain — In this Healio Video Perspective from the Euretina meeting, Francesco Boscia, MD, discusses the role of new anti-VEGF agents in the treatment of pigment epithelial detachment.
Management of pigment epithelial detachments (PEDs) poses significant challenges because they are usually more resistant to compartmentalization of fluid within the retina, he explained.
Newer, more potent agents — brolucizumab, faricimab and aflibercept 8 mg — may lead to faster PED reabsorption but also increased risk for atrophy and visual acuity loss.
“The challenge is to